Headquartered in Philadelphia, PA Fiscal year ends December NASDAQ: CABA cabalettabio.com
Cabaletta Bio is a pre-revenue, late-stage clinical biotechnology company developing targeted cell therapies for patients with autoimmune diseases. Its lead product candidate, resecabtagene autoleucel (rese-cel), is an investigational 4-1BB-containing, fully human CD19-CAR T cell therapy. It is given as a single, weight-based intravenous infusion after patients discontinue immunomodulators, with the aim of producing an immune reset.
Rese-cel is being studied across the company-sponsored REstoring SElf-Tolerance (RESET) program, which spans rheumatology, neurology and dermatology:
- RESET-Myositis: registrational dermatomyositis/antisynthetase syndrome cohort, with topline data expected 2H27 and a planned BLA in 1Q28; also includes a juvenile dermatomyositis cohort.
- RESET-SSc: registrational cohort in systemic sclerosis with interstitial lung disease.
- RESET-SLE: lupus and lupus nephritis.
- RESET-MG: myasthenia gravis.
- RESET-PV: pemphigus vulgaris.
The company is also developing a preconditioning-free (PC-free) dosing approach and outpatient dosing options to broaden rese-cel's potential use. Updated
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or…
Cabaletta Bio is a pre-revenue, late-stage clinical biotechnology company developing targeted cell therapies for patients with autoimmune diseases. Its lead product candidate, resecabtagene autoleucel (rese-cel), is an investigational 4-1BB-containing, fully human CD19-CAR T cell therapy.
The Wall Street consensus 12-month price target for CABA is $12.00.
